35 results on '"Sun, Haowei"'
Search Results
2. Vitrification induces a focused spindle pole in mouse MI oocytes
3. Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia
4. Frequency and utility of bone marrow examination in relapsed/refractory immune thrombocytopenia
5. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
6. Incidence of bleeding and thromboembolism and impact on overall survival in adult patients with hemophagocytic lymphohistiocytosis: A 20‐year provincial retrospective cohort study
7. Exploration and Preparation of Patient-specific Ciprofloxacin Implants Drug Delivery System Via 3D Printing Technologies
8. The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
9. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
10. Comparison of Activated Clotting Time to Hepcon Protamine Titration for Anticoagulation Management during Cardiopulmonary Bypass Surgery in a Patient with Severe Hemophilia a on Emicizumab Prophylaxis
11. Prevalence and Risk Factors of Diagnostic Delays in Acquired Hemophilia A
12. Rates and Predictors of Prophylaxis in Women with Von Willebrand Disease and Heavy Menstrual Bleeding
13. Appropriateness of Immunosuppression and Blood Product Utilization in Acquired Hemophilia A: A Multicentre Provincial Practice Audit
14. Case Series of Paraspinal Extramedullary Hematopoiesis in Transfusion-Dependent Thalassemia Treated with Luspatercept
15. Predictors of Diagnostic Delays and Loss to Follow-up in Women with Von Willebrand Disease
16. The Empower Study - Design of a Randomized Clinical Trial to Assess the Efficacy and Safety of a Plasma-Derived Von Willebrand Factor / Factor VIII Concentrate for Heavy Menstrual Bleeding in Women with Von Willebrand Disease
17. Management and Outcomes of Venous Thromboembolism in Adults with Immune Thrombocytopenia
18. Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia
19. Geographic Remoteness Is Associated with Increased Blood Product Utilization and Higher Rates of Hospitalization and Deaths in Adults with Immune Thrombocytopenia
20. Outcomes and Health Resource Utilization Among Second-Line Therapies for Immune Thrombocytopenia: A Provincial Retrospective Cohort Study
21. Impact of Inherited Bleeding Disorders on Maternal Bleeding and Other Pregnancy Outcomes: A Population-Based Cohort Study
22. All Cause Mortality and Causes of Death in People with Hemophilia: A Systematic Review and Meta Analysis
23. Practice Patterns and Outcomes of Hemophagocytic Lymphohistiocytosis in Adults: A Two-Decade Provincial Retrospective Review
24. External Validation of the HLH-2004 Diagnostic Criteria and H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adults
25. Immediate and Long-Term Outcomes Following Orthopedic Procedures in Patients with Hemophilia: A Three-Decade Retrospective Review
26. Survival Pattern Among Venous Thromboembolism (VTE) Patients with Hematologic Malignancy in Alberta, Canada from 2003 to 2015
27. Validation of the Plasmic Score for Predicting ADAMTS13 Activity < 10% in Patients Admitted to Hospitals in Alberta with Suspected Thrombotic Thrombocytopenic Purpura
28. Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada
29. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Subjects With Severe Hemophilia A With Inhibitors at High Risk for ITI Failure
30. Hematuria Is Not a Risk Factor for the Hypertension of Hemophilia
31. Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia
32. Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),
33. Neutropenia and G-CSF Use In Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide Plus Dexamethasone
34. Incidence and Characteristics of Secondary Myelodysplastic Syndrome Developing During Lenalidomide-Based Regimens In Relapsed and/or Refractory Multiple Myeloma Patients
35. Characteristics of Patients Presenting with Secondary Myelodysplastic Syndrome During Treatment with Lenalidomide for Relapsed/Refractory Multiple Myeloma: 5q Deletions Can Be Observed
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.